BCRX  Biocryst Pharmaceuticals Inc.

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.

239.08M

Vuru Grade

23.50/100

Current Price

$3.26
-0.06 (-1.81%)

Company Metrics

  • P/E 0
  • P/S 5.05
  • P/B 3.8
  • EPS -0.59
  • Cash ROIC -251.78%
  • Cash Ratio 0.80
  • Dividend 0 / 0%
  • Avg. Vol. 1.61M
  • Shares 73.34M
  • Market Cap. 239.08M

Company Description

BioCryst Pharmaceuticals, Inc. designs, optimizes, and develops small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. It uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry, and computer modeling to develop new therapeutic candidates. The com... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

How Many BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)'s Analysts Are Bullish?
Franklin Independent - 23 hours ago
Out of 9 analysts covering BioCryst Pharmaceuticals (NASDAQ:BCRX), 4 rate it a “Buy”, 1 “Sell”, while 5 “Hold”.
BioCryst Pharmaceuticals, Inc. (BCRX) Short Interest Down 21.9% in April - Web Breaking News
BioCryst Pharmaceuticals, Inc. (BCRX) has potential to increase 313 percent
CWRU Observer - Apr 26, 2016
BioCryst Pharmaceuticals, Inc. (BCRX) has just caught the analyst's attention after adding 5.22 percent in the last trading session.
Biocryst Pharmaceuticals (BCRX) Stock: Weak On High Volume Today - TheStreet.com
Today's Stocks: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), Comcast ... - Stock Transcript
Stock's Buzz on These Trending Stocks BioCryst Pharmaceuticals, Inc. (NASDAQ ...
The Point Review - Apr 25, 2016
Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) flew 4.78% to $3.62 at 12:37PM EDT. The stock attained the volume of 831,301 shares recently versus average trading volume of 1.15 Million shares.
Two Biotechnology Names Are Hot: bluebird bio, Inc. (BLUE), BioCryst ... - Zergwatch
Schwab Charles Investment Management Inc. Acquires 20210 Shares of BioCryst ... - The Vista Voice
BioCryst Pharmaceuticals Inc. (BCRX) Drops 5.79% on April 26
Equities.com - Apr 27, 2016
BioCryst Pharmaceuticals Inc. (BCRX) was one of the Russell 2000's biggest losers for Tuesday April 26 as the stock slid 5.79% to $3.42, a loss of $-0.21 per share.
Stock Update (NASDAQ:BCRX): BioCryst Pharmaceuticals, Inc. Announces Clinical ...
Smarter Analyst - Feb 8, 2016
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced results from OPuS-2 (Oral ProphylaxiS-2), a clinical trial of avoralstat administered three times daily as a liquid-filled soft gel formulation for the prophylactic treatment of hereditary ...
Is BioCryst Reaching Crush Depth? - 24/7 Wall St.
BioCryst Pharmaceuticals, Inc Crashes on Failure of OPuS 2 Clinical Trial for HAE - Bidness ETC
BioCryst Pharmaceuticals Inc. (BCRX) Jumps 7.35% on April 21
Equities.com - Apr 21, 2016
BioCryst Pharmaceuticals Inc. (BCRX) was among the biggest gainers on the Russell 2000 for Thursday April 21 as the stock popped 7.35% to $3.36, representing a gain of $0.23 per share.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Recommendation ...
The Vista Voice - Apr 20, 2016
BioCryst Pharmaceuticals logo Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have earned an average recommendation of “Hold” from the fourteen ratings firms that are presently covering the firm, Analyst Ratings Network.
Two Biotechnology Names Are Hot: BioCryst Pharmaceuticals, Inc. (BCRX ... - Zergwatch
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Latest Broker Views - Risers & Fallers
What do analysts say about? Peabody Energy Corporation (BTU), BioCryst ...
Beacon Chronicle - Mar 25, 2016
Last Trade:The Company closed its last session at $2.56 yesterday with the gain of 6.67%. The market capitalization of the company is $50.62 Million, with the average Volume of $4.79 Million. Recent Announcement: Peabody Energy Corporation (BTU) as ...
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Price Target Changes - Risers & Fallers
Here's Why Shares of BioCryst Pharmaceuticals, Inc. Are Falling Today
Motley Fool - Oct 8, 2015
What: Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX), a biotech company that specializes in the development of small molecular drugs, sank by over 20% today on heavy volume.
BioCryst Pharmaceuticals (BCRX) Stock Drops Despite Positive Drug Trial Results - TheStreet.com
BioCryst Shares Drop Sharply Following Early-Stage Drug Results - Wall Street Journal
BioCryst Pharmaceuticals, Inc. (BCRX) Zooms Higher on Zika Data
Schaeffers Research (blog) - Mar 7, 2016
Drugmaker BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is surging 22.7% to $3.17 today, after announcing that a preclinical study in mice showed promising results of an antiviral treatment for the Zika virus.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Tests Zika Drug On Mice, Gets ... - Journal Transcript
BioCryst's Zika drug shows promise in mice - Reuters